Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

RNA interference therapy in cardiology: will new targets improve therapeutic goals?

Therapeutic siRNA: State-of-the-Art and Future Perspectives

RNA in cardiovascular disease: A new frontier of personalized medicine

RNA-based Therapeutics: an Overview and Prospectus

RNA Therapeutics for the Cardiovascular System

RNAi-based drug design: considerations and future directions

Safety and effectiveness of interference RNA (RNAi) based therapeutics in cardiac failure: A systematic review

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease

RNA interference-based therapies for atherosclerosis: Recent advances and future prospects

Recent Advances and Prospects in RNA Drug Development

RNA interference in the era of nucleic acid therapeutics

The current state and future directions of RNAi-based therapeutics

RNA Therapeutics - Research and Clinical Advancements

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Current RNA strategies in treating cardiovascular diseases

Small non-coding RNA therapeutics for cardiovascular disease

Current Advances in RNA Therapeutics for Human Diseases

Innovative developments and emerging technologies in RNA therapeutics

The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market

Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets

Innovative hypertension treatments: transitioning from conventional therapies to siRNA-based solutions